Elunetirom

ID: elunetirom

Aliases: ABX-002, MA-JD21

Type: compound

Route/form: oral investigational drug

Status: investigational

Evidence level: early human

Best data tier: early human

Support scope: human, non-human/mechanistic, review/regulatory, context

Source types: clinical_trial_registry, database, early_human, medicinal_chemistry

Linked sources: 4

Broad outcomes: Brain / mood / sleep

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• thyroid hormone receptor beta agonist
• CNS-directed thyromimetic

Optimization domains

• depression
• bipolar depression
• CNS
• myelin

Research basis

• Phase 1 human safety/PK/PD data and active Phase 2 registry entries provide a real development anchor.
• TR-beta/CNS thyromimetic rationale links to plasticity and remyelination hypotheses, with identity/prodrug pharmacology tracked by IUPHAR/BPS.

Limits, risks, and missing evidence

• No posted Phase 2 efficacy results in this seed pass.
• Thyroid-axis, cardiac, bone, and psychiatric activation questions must be watched carefully.

Risk flags

• investigational
• thyroid axis
• medical supervision

Linked papers, labels, and reviews

1. Phase 1 safety, PK, and pharmacodynamics study of ABX-002 in healthy adult participants
   early_human / oxford_abx002_phase1_2025
   Endocrine Society abstract for ABX-002/elunetirom SAD/MAD human phase 1 data.
2. NCT06633016 - Study of ABX-002 for adjunctive treatment of major depressive disorder
   clinical_trial_registry / ctgov_abx002_mdd_2026
   Phase 2 trial record; no posted efficacy results at curation time.
3. IUPHAR/BPS Guide to Pharmacology ligand page for elunetirom
   database / guidetopharmacology_elunetirom
   Identity, synonym, prodrug, active-metabolite, and TR-beta pharmacology reference.
4. Thyromimetics with improved selectivity for thyroid hormone receptor beta
   medicinal_chemistry / pubmed_thr_beta_thyromimetics_2004
   Background on TR-beta selective agonist design.